Monitoring the price of new drugs

Silversides, Ann
May 2006
CMAJ: Canadian Medical Association Journal;5/23/2006, Vol. 174 Issue 11, p1548
Academic Journal
Reports on the need for tribunal in charge of regulating drug prices in Canada to monitor the price of new drugs, rather than the annual price increases posted by manufacturers on already-marketed drugs. Option for manufacturers to increase prices according to a formula based on the Consumer Price Index; Major factor behind increased retail spending on drugs; Arguments raised by drug manufacturers on the issue.


Related Articles

  • Canada's Pharmaceutical Price Control Paradox. Brett J. Skinner // Fraser Forum;Jun2005, p12 

    Presents a question and answer advisory about the practices of the drug price control in Canada. Role of the Patented Medicines Prices Review Board in enforcing drug price regulations; Applicability of federal drug price regulations to the legal class of drugs known as patented drugs; Influence...

  • PHARMACEUTICAL PRICING AND REIMBURSEMENT POLICIES IN SWITZERLAND. Paris, ValĂ©rie; Docteur, Elizabeth // OECD Papers;2007, Vol. 7 Issue 6, p1 

    The article assesses the economic policies of Switzerland specially its pharmaceutical pricing and reimbursement policies. Such assessment, accordingly, is in line with the assessing of the direct impact of the policies of the country as well. It is claimed that the country's pharmaceutical...

  • High Drug Prices: For Research or Profit? Wolfe, Sidney // Pharmaceutical Executive;Mar2001, Vol. 21 Issue 3, p146 

    Focuses on several issues disputing the need for United States (U.S.) pharmaceutical companies to control drug prices in order to facilitate research for new treatments. Profit margin of U.S. pharmaceutical companies in 2000; Percentage of drug companies' budgets devoted to research and...

  • Pharmaceutical price regulation. A study on the impact of the rate-of-return regulation in the UK. Borrell, J-R. // PharmacoEconomics;1999, Vol. 15 Issue 3, p291 

    Objective: This work carries out an empirical evaluation of the impact of the main mechanism for regulating the prices of medicines in the UK [the Pharmaceutical Price Regulation Scheme (PPRS)] on a variety of pharmaceutical price indices. The article also discusses to what extent...

  • Drug marketing practices facing new investigation.  // Medical Marketing & Media;Mar2001, Vol. 36 Issue 3, p6 

    Focuses on the role of the U.S. Congress in investigating the marketing practices of pharmaceutical companies before enacting a Medicare drug benefit provision. Submission of written comments on the impact of marketing practices on drug costs; Implementation of government price control; Views...

  • O, CANADA! WHERE LOW DRUG PRICES ARE COSTLY TO YOUR HEALTH. Freese, Duane D. // Saturday Evening Post;Sep/Oct2003, Vol. 275 Issue 5, p38 

    Analyzes the disadvantage and danger posed by the lower drug prices in Canada. Comparison between the prices of drugs in Canada and the U.S.; Reasons for the difference between the prices in the two countries; Status of the pharmaceutical industry in Canada as of August 2003.

  • Readers Weigh In.  // Pharmaceutical Executive;Oct2015, Vol. 35 Issue 10, p10 

    Three letters to the editor are presented in response to the articles "The Pre-Gouging Price," "The Pathway to Public Rx Price Controls in 2016," and "Pharma Exec's 14th Annual Industry Audit."

  • Debate on drug prices in eastern Germany. Karcher, Helmut L. // BMJ: British Medical Journal (International Edition);2/2/91, Vol. 302 Issue 6771, p254 

    Debates on the regulation of drug prices in Eastern Germany. Price discount for drugs; Development of drug sales; Amount contributed by the pharmaceutical industry to compensate for the health insurance deficit.

  • UK Pricing Examined. Houlton, Sarah // Pharmaceutical Executive;Nov2005, Vol. 25 Issue 11, p24 

    Reports on the examination of the Pharmaceutical Price Regulation Scheme (PPRS) by the Office of Fair Trading in Great Britain. Role of the scheme in the regulation of profits of the drug companies; Determination whether the PPRS works well to ensure that pharmaceutical markets meet the needs of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics